Axon Enterprise, Inc.

AXON

CIK 0001069183 · Quarterly mode · latest period FY2025 (Q4) (ending 2025-12-31) · sourced from SEC EDGAR

At a glance · FY2025 (Q4)

Revenue
$797M
↑+38.5% +$222Mvs FY2024 (Q4)
Gross Profit
$461M
↑+33.4% +$115Mvs FY2024 (Q4)

Quality Score

Quality score

6-dimension fundamental snapshot · latest annual filed values · S&P 500 calibration

Average
49/100
  • Profitability
    0ROIC -1.5% (10% = solid, 20%+ = moat)
  • Liquidity
    100Current Ratio 2.53 (above 1.5 = solid)
  • Leverage
    72D/E 0.56 (under 0.5 = conservative)
  • Efficiency
    22Asset Turnover 0.48x (1.0+ = capital-efficient)
  • Growth
    100Revenue YoY +38.5% (10% = solid, 25%+ = elite)
  • Margin Trend
    0Op Margin -0.3% · trend -5.5pts (4Q avg vs prior 4Q)

Calibrated to S&P 500 medians. Each sub-score is computed from a single CFA-grade ratio (Profitability = ROIC, Liquidity = Current Ratio, Leverage = D/E, Efficiency = Asset Turnover, Growth = Revenue YoY, Margin Trend = 4Q operating-margin avg vs prior 4Q). Overall = simple mean.

DCF intrinsic value

DCF intrinsic value

two-stage Gordon model

Project AXON's free cash flow forward, discount back at your hurdle rate, divide by diluted shares. Edit the assumptions to see how sensitive the intrinsic value is.

3%

Trailing 3-yr CAGR was -25.2%

10%

10% is a common all-equity benchmark for US large-caps

2.5%

Should be ≤ long-run GDP growth (~2.5% nominal)

5

5-year explicit projection + perpetuity terminal

Intrinsic value per share
$12.72
Total enterprise IV
$1.05B
Diluted shares
0.08B
Terminal PV
$739M (70% of total)
Year-5 FCF
$87M
YearProjected FCFDiscounted PV
+1$77M$70M
+2$80M$66M
+3$82M$62M
+4$85M$58M
+5$87M$54M
Terminal$1.19B$739M

DCF outputs are HIGHLY sensitive to growth + WACC assumptions. A 1pp WACC change can shift IV by 20%+. Use this as a sanity-check vs market price, not a target — and always cross-check the underlying FCF source (EDGAR cashflow statement, latest annual). Margin of safety convention: 30-50% discount to IV before buying.

Capital allocation · trailing 4 quarters

how the company spent its cash
Capex (TTM)
$136M
investment in PP&E
Stock buybacks (TTM)
share count reduction
Stock-based comp (TTM)
$634M
non-cash dilution

Balance sheet · 2025-12-31

latest filed snapshot
Total assets
$7.00B
everything owned
Total liabilities
$3.76B
everything owed
Stockholders' equity
$3.24B
shareholder claim
Net debt
$610M
LT debt minus cash

Recent performance · 63 quarters

Revenue↑+38.5% +$222M
$797M
Net Income↓-98.0% -$132M
$3M
Free Cash Flow↓-31.0% -$70M
$155M
Operating Margin↓-4.7pts
-0.3%

Drill down